INTERNATIONAL PATENT: SELLAS LIFE SCIENCES GROUP, INC. FILES APPLICATION FOR "A CDK9 INHIBITOR FOR USE IN THE TREATMENT OF CANCER IN A SUBJECT HAVING AN ASXL1 MUTATION"

GENEVA, Oct. 20 -- SELLAS LIFE SCIENCES GROUP, INC. (7 Times SquareSuite 2503New York City, New York 10026) filed a patent application (PCT/US2025/024396) for "A CDK9 INHIBITOR FOR USE IN THE TREATMENT OF CANCER IN A SUBJECT HAVING AN ASXL1 MUTATION" on Apr 11, 2025. With publication no. WO/2025/217597, the details related to the patent application was published on Oct 16, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): CICIC, Dragan (7 Times SquareSuite 2503New York City, New York 10026), STERGIOU, Angelos M. (7 Times SquareSuite 2503New York, New York 10026), KADIA, Tapan (7 Times SquareSu...